» Articles » PMID: 35909324

Soluble Lectin-like Oxidized Low-density Lipoproteinreceptor-1 and Recurrent Stroke: A Nested Case-control Study

Overview
Specialties Neurology
Pharmacology
Date 2022 Aug 1
PMID 35909324
Authors
Affiliations
Soon will be listed here.
Abstract

Main Problem: The prognostic value of soluble lectin-like oxidized low-density lipoproteinreceptor-1 (sLOX-1) for stroke was unclearly. This study aimed to investigate the association between sLOX-1 and recurrent stroke in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA).

Methods: Data were obtained from the Third China National Stroke Registry. Eligible cases consisted of 400 patients who developed recurrent stroke within 1-year follow-up, 800 controls were selected using age- and sex-matched with a 1:2 case-control ratio. Conditional logistic regressions were used to evaluate the association between sLOX-1 and recurrent stroke.

Results: Among 1200 patients included in this study, the median (interquartile range) of sLOX-1 was 247.12 (132.81-413.58) ng/L. After adjustment for conventional confounding factors, the odds ratio with 95% confidence interval in the highest tertile versus the lowest tertile was 2.23 (1.61-3.08) for recurrent stroke, 2.31 (1.64-3.24) for ischemic stroke, 2.30 (1.66-3.19) for combined vascular events within 1-year follow-up. Furthermore, the addition of sLOX-1 to a conventional risk model had an incremental effect on predictive value for recurrent stroke (C-statistics 0.76, p < 0.0001; integrated discrimination improvement 13.38%, p < 0.0001; net reclassification improvement 55.39%, p < 0.0001). Similar results were observed when the timepoint was set up as 3 months. Subgroup analysis showed the association between higher sLOX-1 and recurrent stroke was more pronounced in patients with a history of stroke (p for interaction = 0.0062).

Conclusions: sLOX-1 was positively associated with the risk of recurrent stroke, which may be a candidate biomarker to improve risk stratification of recurrent stroke.

Citing Articles

Prognostic Value of Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 for Future Cardiovascular Disease Risk and Outcome: A Systematic Review and Meta-Analysis.

Aminuddin A, Samah N, Che Roos N, Mohamad S, Beh B, A Hamid A Biomedicines. 2025; 13(2).

PMID: 40002857 PMC: 11853656. DOI: 10.3390/biomedicines13020444.


Soluble lectin-like oxidized low-density Lipoproteinreceptor-1 and recurrent stroke: A nested case-control study.

Wang A, Tian X, Xu J, Li H, Xu Q, Chen P CNS Neurosci Ther. 2022; 28(12):2001-2010.

PMID: 35909324 PMC: 9627350. DOI: 10.1111/cns.13932.

References
1.
Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M . LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem. 2010; 56(4):550-8. DOI: 10.1373/clinchem.2009.140707. View

2.
Szmitko P, Wang C, Weisel R, Jeffries G, Anderson T, Verma S . Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation. 2003; 108(17):2041-8. DOI: 10.1161/01.CIR.0000089093.75585.98. View

3.
He X, Zeng Y, Li G, Feng Y, Wu C, Liang F . Extracellular ASC exacerbated the recurrent ischemic stroke in an NLRP3-dependent manner. J Cereb Blood Flow Metab. 2019; 40(5):1048-1060. PMC: 7181081. DOI: 10.1177/0271678X19856226. View

4.
Wang A, Tian X, Xu J, Li H, Xu Q, Chen P . Soluble lectin-like oxidized low-density Lipoproteinreceptor-1 and recurrent stroke: A nested case-control study. CNS Neurosci Ther. 2022; 28(12):2001-2010. PMC: 9627350. DOI: 10.1111/cns.13932. View

5.
Deng W, Deng Y, Deng J, Wang D, Zhang T . Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1. Int J Clin Exp Pathol. 2016; 8(12):15670-6. PMC: 4730049. View